SCHEMBL7123072

SCHEMBL7123072

O=C(Nc1ccc(Cl)c(Cl)c1)c1ccccc1NS(=O)(=O)c1ccccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.58
MEN1 O00255 9/20 0.58
TSHR P16473 1/20 0.51
MAPT P10636 6/20 0.50
KDM4E B2RXH2 4/20 0.50
GRM4 Q14833 3/20 0.50
HTT P42858 3/20 0.50
SMN1; SMN2 Q16637 6/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
FADS1 O60427 1/20 0.49
ALDH1A1 P00352 4/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 1/20 0.48
SLC10A2 Q12908 1/20 0.48
SLC10A1 Q14973 1/20 0.48
SLC10A6 Q3KNW5 1/20 0.48
CCR2 P41597 1/20 0.48
NFKB1 P19838 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128109 0.87 MEN1 (0.64) KMT2AMEN1TSHRMAPTKDM4E
SCHEMBL7213175 0.86 SLC20A2 (0.54) KMT2AMEN1TSHRMAPTKDM4E
SCHEMBL7208746 0.84 TSHR (0.58) KMT2AMEN1TSHRMAPTKDM4E
SCHEMBL7533748 0.83 CCR2 (0.53) KMT2AMEN1MAPTKDM4EGRM4
SCHEMBL4251978 0.80 NPC1 (0.71) KMT2AMEN1MAPTKDM4EGRM4
SCHEMBL7563545 0.78 CCR2 (0.48) KMT2AMEN1MAPTKDM4EHTT
SCHEMBL28454669 0.78 MEN1 (0.64) KMT2AMEN1LMNASLC10A2SLC10A1
SCHEMBL7208733 0.77 SLC10A6 (0.71) KMT2AMEN1MAPTKDM4EHTT
SCHEMBL20560717 0.77 SLC10A2 (0.70) KMT2AMEN1MAPTKDM4EHTT
SCHEMBL21328495 0.77 SLC25A1 (0.54) KMT2AMEN1TSHRMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US claimed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP claimed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO claimed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO claimed
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US disclosed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP disclosed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO disclosed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216449-A1 Phosphate transport inhibitors SLC34A2, SLC34A1, SLC34A3 KMT2A 4033/4885MEN1 3779/4885TSHR 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.